FDAnews Drug Daily Bulletin

Although it is up to sponsors and investigators whether to file an IND application, institutional review boards (IRB) still need to review those decisions, according to FDA draft guidance. In cases where the sponsor and investigator have decided not to file, the IRB should request documentation to substantiate the decision, such as a letter from the sponsor or the FDA.
Drug Industry Daily